Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C F Stewart

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Pharmacodynamic model of topotecan-induced time course of neutropeniaW C Zamboni, D Z D'Argenio, C F Stewart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft modelsW C Zamboni, C F Stewart, P J Cheshire, et al.
Bone Marrow Transplantation|October 19, 2001
Topotecan-filgrastim combination is an effective regimen for mobilizing peripheral blood stem cellsE J Yeoh, J M Cunningham, G C Yee, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 22, 1998
Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretionW C Zamboni, P J Houghton, R K Johnson, et al.
Journal of Pediatric Hematology/Oncology|November 1, 1996
Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group studyD G Tubergen, C F Stewart, C B Pratt, et al.
Bone Marrow Transplantation|March 20, 2012
A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-upK A Kasow, C F Stewart, R C Barfield, et al.
Cancer Chemotherapy and Pharmacology|May 13, 1999
Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumorsW C Zamboni, L C Bowman, M Tan, et al.
Clinical Pharmacology and Therapeutics|August 9, 2012
Concordance of DMET plus genotyping results with those of orthogonal genotyping methodsC A Fernandez, C Smith, W Yang, et al.
British Journal of Cancer|October 14, 2015
Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRIJ Guo, J O Glass, M B McCarville, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in childrenW L Furman, C F Stewart, C A Poquette, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Pharmacodynamic model of topotecan-induced time course of neutropeniaW C Zamboni, D Z D'Argenio, C F Stewart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft modelsW C Zamboni, C F Stewart, P J Cheshire, et al.
Bone Marrow Transplantation|October 19, 2001
Topotecan-filgrastim combination is an effective regimen for mobilizing peripheral blood stem cellsE J Yeoh, J M Cunningham, G C Yee, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 22, 1998
Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretionW C Zamboni, P J Houghton, R K Johnson, et al.
Journal of Pediatric Hematology/Oncology|November 1, 1996
Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group studyD G Tubergen, C F Stewart, C B Pratt, et al.
Bone Marrow Transplantation|March 20, 2012
A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-upK A Kasow, C F Stewart, R C Barfield, et al.
Cancer Chemotherapy and Pharmacology|May 13, 1999
Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumorsW C Zamboni, L C Bowman, M Tan, et al.
Clinical Pharmacology and Therapeutics|August 9, 2012
Concordance of DMET plus genotyping results with those of orthogonal genotyping methodsC A Fernandez, C Smith, W Yang, et al.
British Journal of Cancer|October 14, 2015
Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRIJ Guo, J O Glass, M B McCarville, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in childrenW L Furman, C F Stewart, C A Poquette, et al.
Pageof 10